{"title":"[奥西替尼-局部晚期非小细胞肺癌EGFR外显子19缺失或外显子21 L858R突变放化疗后维持治疗]。","authors":"Lisa Bosquain , Olivier Bylicki","doi":"10.1016/j.bulcan.2025.03.015","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 7","pages":"Pages 693-694"},"PeriodicalIF":0.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Osimertinib en traitement d’entretien après radiochimiothérapie dans les cancers bronchiques non à petites cellules localement avancés avec délétion de l’exon 19 ou mutation L858R de l’exon 21 de l’EGFR\",\"authors\":\"Lisa Bosquain , Olivier Bylicki\",\"doi\":\"10.1016/j.bulcan.2025.03.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9365,\"journal\":{\"name\":\"Bulletin Du Cancer\",\"volume\":\"112 7\",\"pages\":\"Pages 693-694\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin Du Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0007455125002619\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin Du Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0007455125002619","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Osimertinib en traitement d’entretien après radiochimiothérapie dans les cancers bronchiques non à petites cellules localement avancés avec délétion de l’exon 19 ou mutation L858R de l’exon 21 de l’EGFR
期刊介绍:
Without doubt, the ''Bulletin du Cancer'' is the French language publication of reference in the field of cancerology. Official organ of the French Society of Cancer, this journal covers all the information available, whether in the form of original articles or review articles, but also clinical cases and letters to the editor, including various disciplines as onco-hematology, solids tumors, medical oncology, pharmacology, epidemiology, biology as well as fundamental research in cancerology. The journal proposes a clinical and therapeutic approach of high scientific standard and regular updates in knowledge are thus made possible. Articles can be submitted in French or English.